Yellowbird Diagnostics Initiates First-in-Human Trial of Novel Inflammation Imaging Agent NeuCaVis
Key Insights
Yellowbird Diagnostics (search) has successfully dosed the first participants in a Phase I clinical trial of NeuCaVis (search)™, a first-in-class PET imaging agent that targets fructose metabolism (search) to visualize inflammation (search) with high specificity.
The single-dose, open-label study is being conducted at the University of Ottawa Heart Institute to evaluate safety, tolerability, and dosimetry in healthy volunteers, with completion anticipated by June 2026.
NeuCaVis (search)™ represents a new paradigm in molecular imaging by providing direct visualization of inflammatory activity with minimal background signal, potentially enabling earlier and more accurate detection of cardiovascular diseases (search), chronic inflammatory disorders (search), neuroinflammation (search), and cancer (search).
Yellowbird Diagnostics (search) Inc. has achieved a significant milestone in molecular imaging with the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis (search)™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation (search). The Ottawa-based biotechnology company announced this development as the first pipeline asset from its platform to enter clinical development.
Revolutionary Approach to Inflammation Detection
NeuCaVis (search)™ represents a paradigm shift in medical imaging by targeting fructose metabolism (search), a key pathway associated with inflammatory activity. Unlike conventional imaging approaches, this first-in-class PET tracer enables direct visualization of fructose metabolism, providing a potentially more specific signal of inflammatory activity across multiple disease areas.
The technology has demonstrated potential to support earlier and more accurate detection of a broad range of serious conditions, including cardiovascular diseases (search), chronic inflammatory disorders (search), neuroinflammation (search), and cancer (search). Preclinical and early human data suggest that NeuCaVis (search)™ demonstrates minimal background signal, with uptake observed primarily in tissues with active inflammation (search).
Phase I Trial Design and Leadership
The single-dose, open-label Phase I study is being conducted at the University of Ottawa Heart Institute under the leadership of Dr. Benjamin Chow. The trial is specifically designed to evaluate the safety, tolerability, and dosimetry of NeuCaVis (search)™ in healthy volunteers, with completion anticipated by June 2026.
"There is a critical need in cardiology for more precise imaging of inflammatory processes," said Dr. Benjamin Chow, Lead Investigator. "Based on early observations, NeuCaVis (search)™ shows promise as a technology that could enhance diagnostic confidence and ultimately improve patient management."
Clinical Significance and Market Impact
Inflammation (search) serves as a central driver of many major diseases, yet remains difficult to image with precision using current technologies. The targeted signal profile of NeuCaVis (search)™ may enable improved diagnostic clarity and more informed clinical decision-making, addressing a significant unmet medical need in the field of molecular imaging.
"Dosing our first patients marks a significant milestone for Yellowbird and for the field of molecular imaging," said Adam Shuhendler, Chief Scientific Officer and Co-Founder of Yellowbird Diagnostics (search). "Our goal is to move beyond the limitations of conventional PET imaging and deliver tools that provide clearer, more actionable insights for clinicians and patients."
Company Background and Support
Yellowbird Diagnostics (search) is developing next-generation metabolic imaging agents to detect disease earlier and guide clinical decision-making. The company is led by Co-Founders Nicholas D. Calvert (Chief Executive Officer), Alexia Kirby (Chief Operating Officer), and Adam Shuhendler (Chief Scientific Officer), with Michael Gottlieb serving as Executive Board Chair.
The NeuCaVis (search)™ Phase I program has garnered substantial support from multiple organizations, including Brain and Heart Interconnectome, Capital BioVentures, FACIT, Canadian Medical Isotope Ecosystem, Ontario Brain Institute, University of Ottawa Heart Institute, and Yellowbird's investor base.